首页> 外国专利> E. coli BL21 (DE3)/pTEV-TMS STRAIN - FUSION PROTEIN TrxTEVrs-TMS PRODUCER, DESTINED FOR PROTEOLYTIC CLEAVAGE WITH TUMSTATIN ANTI-ANGIOGENIC PEPTIDE FORMATION, HUMAN TUMSTATIN FRAGMENT L69K-95 DERIVATIVE, AND METHOD FOR RECOMBINANT ANTI-ANGIOGENIC PEPTIDE PRODUCTION

E. coli BL21 (DE3)/pTEV-TMS STRAIN - FUSION PROTEIN TrxTEVrs-TMS PRODUCER, DESTINED FOR PROTEOLYTIC CLEAVAGE WITH TUMSTATIN ANTI-ANGIOGENIC PEPTIDE FORMATION, HUMAN TUMSTATIN FRAGMENT L69K-95 DERIVATIVE, AND METHOD FOR RECOMBINANT ANTI-ANGIOGENIC PEPTIDE PRODUCTION

机译:大肠杆菌BL21(DE3)/ pTEV-TMS菌株-融合蛋白TrxTEVrs-TMS生产商,旨在通过肠胃抑素抗血管肽的形成,人胃抑素片段[L69K-95]变性胶粘剂和方法用于蛋白水解生产

摘要

FIELD: biotechnology.;SUBSTANCE: method for recombinant anti-angiogenic Tumastin peptide a - human tumstatin modified fragment [L69K-95] derivative with Ser-Gly-Ala-Met-Gly and Pro-Gly-Pro sequences attached to N- and C-termini, respectively, provides culturing of E. coli BL21 (DE3)/pTEV-TMS producing strain, destruction of cell biomass in the presence of protease inhibitors, cell lysate centrifuging and separation of cell supernatant containing fusion protein, fusion protein chromatographic purification on a column with an anion exchange sorbent, proteolytic cleavage by TEV-protease, chromatographic purification of the anti-angiogenic Tumastin peptide.;EFFECT: invention provides high yield of anti-angiogenic Tumastin peptide.;2 cl, 5 dwg, 3 ex
机译:领域:生物技术;方法:重组抗血管生成性Tumastin肽a-人tumstatin修饰的片段[L69K-95]衍生物,其Ser-Gly-Ala-Met-Gly和Pro-Gly-Pro序列附着于N-和C -termini分别提供大肠杆菌BL21(DE3)/ pTEV-TMS产生菌株的培养,蛋白酶抑制剂存在下细胞生物量的破坏,细胞裂解液的离心和含融合蛋白的细胞上清液的分离,融合蛋白的色谱纯化具有阴离子交换吸附剂的柱,通过TEV蛋白酶进行蛋白水解切割,色谱纯化抗血管生成的Tumastin肽。效果:本发明提供了高产率的抗血管生成的Tumastin肽。2cl,5 dwg,3 ex

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号